Trial watch: dexmedetomidine in cancer therapy

Killian Carnet Le Provosta Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy, Université Paris Saclay, Villejuif, FranceView further author information

Oliver Keppa Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy, Université Paris Saclay, Villejuif, FranceView further author information

Guido Kroemera Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy, Université Paris Saclay, Villejuif, France;c Pôle de Biologie, Hôpital européen Georges Pompidou, AP-HP, Paris, FranceCorrespondence[email protected]
View further author information

Lucillia Bezua Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy, Université Paris Saclay, Villejuif, France;d Gustave Roussy, Département Anesthésie, Chirurgie et Interventionnel, Villejuif, FranceCorrespondence[email protected]

https://orcid.org/0000-0002-3569-6066 View further author information

Trial watch: dexmedetomidine in cancer therapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trial watch: dexmedetomidine in cancer therapy

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date